In 2023, one story dominated the headlines for the US biosimilars sector: the debut of biosimilar competition to AbbVie Inc.’s top-selling Humira (adalimumab) immunology brand.
A series of patent settlements between biosimilar sponsors and the originator had paved the way for multiple launches throughout this...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?